Insider Buying: ProQR Therapeutics (NASDAQ:PRQR) Director Buys $231,000.00 in Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was bought at an average price of $1.54 per share, for a total transaction of $231,000.00. Following the completion of the acquisition, the director directly owned 150,000 shares in the company, valued at approximately $231,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

ProQR Therapeutics Stock Up 1.6%

Shares of NASDAQ PRQR traded up $0.03 during mid-day trading on Tuesday, hitting $1.86. 1,032,128 shares of the company traded hands, compared to its average volume of 654,152. ProQR Therapeutics N.V. has a 1 year low of $1.33 and a 1 year high of $3.10. The stock has a market capitalization of $195.97 million, a price-to-earnings ratio of -3.72 and a beta of 0.07. The business has a 50 day moving average of $1.60 and a two-hundred day moving average of $1.71.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15). The firm had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%. As a group, research analysts anticipate that ProQR Therapeutics N.V. will post -0.57 EPS for the current year.

Institutional Trading of ProQR Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Aberdeen Group plc increased its stake in ProQR Therapeutics by 28.4% in the 4th quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock valued at $5,960,000 after buying an additional 651,853 shares during the period. Privium Fund Management B.V. raised its holdings in shares of ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock worth $10,823,000 after acquiring an additional 359,475 shares in the last quarter. Moody Lynn & Lieberson LLC acquired a new stake in ProQR Therapeutics during the fourth quarter valued at $50,000. ArrowMark Colorado Holdings LLC grew its stake in ProQR Therapeutics by 3.9% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,246,234 shares of the biopharmaceutical company’s stock valued at $2,654,000 after purchasing an additional 46,596 shares in the last quarter. Finally, Quadrature Capital Ltd increased its position in ProQR Therapeutics by 188.4% in the 4th quarter. Quadrature Capital Ltd now owns 104,231 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 68,091 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PRQR shares. Wall Street Zen lowered shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings lowered shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective on the stock. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. Finally, Chardan Capital lowered their price target on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.33.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.